Movatterモバイル変換

[0]ホーム
URL:

Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Silverchair Information Systems full text link Silverchair Information Systems Free PMC article
Full text links

Actions

Share

.2019 Sep 1;155(9):1022-1027.
doi: 10.1001/jamadermatol.2019.0891.

Association of Hidradenitis Suppurativa With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis

Affiliations

Association of Hidradenitis Suppurativa With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis

Wei-Ti Chen et al. JAMA Dermatol..

Abstract

Importance: Hidradenitis suppurativa (HS) and inflammatory bowel disease (IBD) are inflammatory diseases that share common genetic susceptibility and immunologic features. However, the link between HS and IBD has been largely unclear.

Objective: To conduct a meta-analysis to investigate the association between HS and IBD.

Data sources: A search of the MEDLINE, Cochrane Central Register of Controlled Trials, and Embase databases yielded 397 relevant studies from inception to June 10, 2018. Two additional studies were supplied by one of the investigators.

Study selection: Case-control, cross-sectional, or cohort studies that examined the odds or risk of IBD in patients with HS were included. No geographic or language limitations were imposed.

Data extraction and synthesis: The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed. The Newcastle-Ottawa Scale was used to assess the risk of bias of included studies. Crohn disease and ulcerative colitis were analyzed separately, and a random-effects model meta-analysis was conducted.

Main outcomes and measures: The odds ratios (ORs) and hazard ratios (HRs) of IBD, Crohn disease, and ulcerative colitis in association with HS.

Results: Five case-control studies, 2 cross-sectional studies, and 1 cohort study with a total of 93 601 unique participants were included. The meta-analysis of case-control and cross-sectional studies showed significant associations of HS with Crohn disease (pooled OR, 2.12; 95% CI, 1.46-3.08) and ulcerative colitis (pooled OR, 1.51; 95% CI, 1.25-1.82). Two case-control studies found significant association of HS with IBD (ORs, 2.16 [95% CI, 1.40-3.34] and 10.00 [95% CI, 1.94-51.50]). One cohort study found an increased risk of IBD in patients with HS (HR, 5.6; 95% CI not reported; P < .002).

Conclusions and relevance: The evidence to date supports an association of HS with IBD. These results suggest that consultation with gastroenterologists should be sought when patients with HS present with recurrent abdominal pain, chronic diarrhea, bloody stool, and body weight loss.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

Figures

Figure 1.
Figure 1.. PRISMA Study Flowchart
CENTRAL indicates Cochrane Central Register of Controlled Trials; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-analyses.
Figure 2.
Figure 2.. Risk of Bias Among Included Studies
The Newcastle-Ottawa Scale was used to access the risk of bias. A green dot denotes low risk of bias; yellow, unclear risk of bias.
Figure 3.
Figure 3.. Forest Plots of the Association of Hidradenitis Suppurativa (HS) With Crohn Disease and Ulcerative Colitis
Data were pooled separately by study design using random-effects model; the inverse variance (IV) technique was used for pooling of measures of effects. OR indicates odds ratio; SE, standard error.
See this image and copyright information in PMC

Comment in

  • doi: 10.1001/jamadermatol.2019.1105

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Zouboulis CC, Desai N, Emtestam L, et al. . European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol. 2015;29(4):619-644. doi:10.1111/jdv.12966 - DOI - PubMed
    1. Kelly G, Hughes R, McGarry T, et al. . Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa. Br J Dermatol. 2015;173(6):1431-1439. doi:10.1111/bjd.14075 - DOI - PubMed
    1. Micheletti RG. Hidradenitis suppurativa: current views on epidemiology, pathogenesis, and pathophysiology. Semin Cutan Med Surg. 2014;33(3)(suppl):S48-S50. doi:10.12788/j.sder.0091 - DOI - PubMed
    1. Guet-Revillet H, Coignard-Biehler H, Jais J-P, et al. . Bacterial pathogens associated with hidradenitis suppurativa, France. Emerg Infect Dis. 2014;20(12):1990-1998. doi:10.3201/eid2012.140064 - DOI - PMC - PubMed
    1. van der Zee HH, Horvath B, Jemec GBE, Prens EP. The association between hidradenitis suppurativa and Crohn’s disease: in search of the missing pathogenic link. J Invest Dermatol. 2016;136(9):1747-1748. doi:10.1016/j.jid.2016.05.102 - DOI - PubMed

Related information

LinkOut - more resources

Full text links
Silverchair Information Systems full text link Silverchair Information Systems Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

[8]ページ先頭
©2009-2025 Movatter.jp